Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies
Vincent J. Willey, PharmD, Sheldon Kong, PhD, Bingcao Wu, MS, Todd Hobbs, MD, Andrea Windsheimer, PharmD, Gaurav Deshpande, MS, PhD, Ozgur Tunceli, PhD, Brian Sakurada, PharmD, Jonathan R. Bouchard, MS, RPh
The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women
Christine Ferro, CHFP, Bruce S. Pyenson, FSA, MAAA, Jocelyn Lau, MPH, Mona Kelkar, MBA, Nancy Phillips, MD, Chi-Wei Lu, PhD, Percy Yeung, PhD, Gloria Bachmann, MD
During the later weeks of pregnancy, pregnant women are often concerned with suspected leakage of amniotic fluid, which, whether preterm or at term, requires evaluation and medical intervention. The rupture of membranes occurs in an estimated 8% to 10% of full-term pregnancies.
Interventions to Reduce Avoidable Pregnancy-Related Emergency Department Visits
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Inflammatory bowel disease (IBD) is a chronic, lifelong disorder of the gastrointestinal tract associated with an unpredictable relapsing and remitting disease course. Ulcerative colitis (UC) and Crohn’s disease (CD) are 2 common phenotypes of IBD. Patients with IBD often have considerable symptom burden despite appropriate treatment, and IBD frequently leads to debilitating complications that may require hospitalization, surgery, and/or the escalation of therapy.
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
Machaon M.K. Bonafede, PhD, MPH, Donna McMorrow, BS, Clare Proudfoot, PhD, Shraddha Shinde, MS, MBA, Andreas Kuznik, PhD, Chieh-I Chen, MPH
This retrospective analysis is based on inpatient medical claims, outpatient medical claims, and pharmacy claims from the Truven Health MarketScan Commercial Database. The database includes claims for approximately 35 million employees and their dependents in fee-for-service and managed care health plans.
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States
Narcolepsy is a chronic, disabling sleep disorder characterized by excessive daytime sleepiness and recurrent periods of sudden, unintentional lapses into sleep during the day. This condition may occur with or without cataplexy, an abrupt and typically bilateral loss of skeletal muscle tone that is often triggered by strong emotion that, when severe, may cause the patient to briefly collapse without losing consciousness.
Accurate Diagnosis of Chronic Diseases Can Reduce Costs and Medical Resource Utilization
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
Raghu Durvasula, MD, MHA, Janet Kelly, PharmD, Anneliese Schleyer, MD, MHA, Bradley D. Anawalt, MD, Shabir Somani, MS, MBA, RPh, FASHP, Timothy H. Dellit, MD
Healthcare expenditures in the United States continue to grow at an unprecedented and unsustainable rate. With the shift to value-based care, healthcare organizations are expected to provide consistent high-quality, safe care while reducing healthcare costs.
Pharmacy & Therapeutics Committees’ New Challenge: Stewardship for Specialty Drugs
Effects of Educational Messaging on Urgent and Emergent Care–Seeking Behaviors Among Publicly Insured Populations
Jesse Cambon, MEng, Tristan Cordier, MS, Elizabeth L. Munnich, PhD, MPP, Andrew Renda, MD, Bobby Kapur, MD, MPH, Shkelzen Hoxhaj, MD, MPH, MBA, Meredith Williams, MD, MBA
Narrow network plans offer limited provider choice, but they are attractive to premium-sensitive healthcare consumers, because premiums and out-of-pocket costs are lower than plans with broader provider networks. However, the intended cost-savings for individuals and health
Opportunities to Improve Urgent and Emergent Care Utilization
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States
Approximately 30,000 new cases of multiple myeloma are diagnosed annually in the United States, and 12,650 deaths annually are attributed to multiple myeloma.
Improved Clinical Outcomes with Newer Multiple Myeloma Therapies Associated with Increased Resource Utilization and Financial Burden
Yuexin Tang, PhD, Xingyue Huang, PhD, Jinan Liu, PhD, R. Ravi Shankar, MD, Michael L. Ganz, PhD, Swapnil Rajpathak, MD, DrPH
Type 2 diabetes mellitus (T2DM) affects approximately 30.3 million individuals in the United States, a number that is expected to grow to almost 36 million by the year 2030.
Impact of Step Therapy Restrictions in Diabetes Care
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO
Page 1 of 12
Results 1 - 10 of 118
Results 1 - 10 of 118